Author:
Nair Ayushi,Greeny Alosh,Nandan Amritasree,Sah Ranjay Kumar,Jose Anju,Dyawanapelly Sathish,Junnuthula Vijayabhaskarreddy,K. V. Athira,Sadanandan Prashant
Abstract
AbstractTuberculosis (TB) remains a significant global health challenge, necessitating innovative approaches for effective treatment. Conventional TB therapy encounters several limitations, including extended treatment duration, drug resistance, patient noncompliance, poor bioavailability, and suboptimal targeting. Advanced drug delivery strategies have emerged as a promising approach to address these challenges. They have the potential to enhance therapeutic outcomes and improve TB patient compliance by providing benefits such as multiple drug encapsulation, sustained release, targeted delivery, reduced dosing frequency, and minimal side effects. This review examines the current landscape of drug delivery strategies for effective TB management, specifically highlighting lipid nanoparticles, polymer nanoparticles, inorganic nanoparticles, emulsion-based systems, carbon nanotubes, graphene, and hydrogels as promising approaches. Furthermore, emerging therapeutic strategies like targeted therapy, long-acting therapeutics, extrapulmonary therapy, phototherapy, and immunotherapy are emphasized. The review also discusses the future trajectory and challenges of developing drug delivery systems for TB. In conclusion, nanomedicine has made substantial progress in addressing the challenges posed by conventional TB drugs. Moreover, by harnessing the unique targeting abilities, extended duration of action, and specificity of advanced therapeutics, innovative solutions are offered that have the potential to revolutionize TB therapy, thereby enhancing treatment outcomes and patient compliance.
Graphical Abstract
Publisher
Springer Science and Business Media LLC
Subject
Pharmaceutical Science,Applied Microbiology and Biotechnology,Biomedical Engineering,Molecular Medicine,Medicine (miscellaneous),Bioengineering
Reference333 articles.
1. Zignol M, Gemert Wv, Falzon D, Sismanidis C, Glaziou P, Floyd K, Raviglione M. Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007–2010. Bull World Health Organ. 2012;90:111–9.
2. Migliori GB, Raviglione MC. Essential tuberculosis. Cham: Springer; 2021.
3. Shukla R, Sethi A, Handa M, Mohan M, Tripathi PK, Kesharwani P. Dendrimer-based drug delivery systems for tuberculosis treatment. In: Kesharwani Prashant, editor. Nanotechnology based approaches for tuberculosis treatment. Amsterdam: Elsevier; 2020.
4. Organization WH: Global tuberculosis report 2013: World Health Organization; 2013.
5. WHO G: Global tuberculosis report 2020. Glob Tuberc Rep 2020.
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献